|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum antibodies to MOG (MOG-IgG) have recently been found to be a biomarker of MOG-IgG-associated disorder (MOGAD), a demyelinating disease distinct from both multiple sclerosis and aquaporin-4-IgG neuromyelitis optica spectrum disorder (AQP4-IgG-positive NMOSD).
|
31743235 |
2020 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we report a patient who was treated with pembrolizumab (a PD-1 monoclonal antibody) for lung adenocarcinoma with brain metastasis, and who developed anti-aquaporin-4 antibody (AQP4-Ab) positive neuromyelitis optica spectrum disorder (NMOSD).
|
31655267 |
2020 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Possible mechanisms that may explain co-existence of NMOSD with TCL include a paraneoplastic syndrome leading to AQP4 antibody production, or a generalized dysfunction of the adaptive immune system.
|
31706113 |
2020 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antibody reactivity against HERV-W env peptides was similar in MOG-IgG associated disorders and MS, but different from AQP4-IgG positive NMOSD.
|
31715457 |
2020 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Experimental animal models of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress and shortcomings.
|
31587392 |
2020 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.
|
31654702 |
2020 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Determining the frequency of longitudinally-extensive transverse myelitis (LETM: T2-lesion ≥3 vertebral segments) in multiple sclerosis (MS) is essential to assess its utility in differentiating from aquaporin-4-IgG (AQP4-IgG) positive neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein-IgG (MOG-IgG) myelitis.
|
31707235 |
2020 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
|
31748853 |
2020 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Case data were collected from 44 patients with AQP4 antibody-positive NMOSD, 53 patients with multiple sclerosis (MS) and 79 age- and sex-matched healthy controls.
|
31729806 |
2020 |
|
Neuromyelitis Optica
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
On histopathological examination, NMOSD samples showed significantly decreased IgG-targeting AQP4 expression on sarcolemma compared with non-NMOSD samples in terms of the area of positive staining and integrated optical density.
|
31786498 |
2020 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
The advent of reliable testing for anti-aquaporin-4 for NMOSD and anti-MOG antibodies has helped significantly; however, diagnosis can remain challenging, especially in sero-negative cases.
|
31582425 |
2020 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience.
|
31566079 |
2019 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Within the CNS autoimmunity control cohort, autoantibodies against aquaporin 4 and high-titer Abs against myelin oligodendrocyte glycoprotein were, as expected, specific for neuromyelitis optica spectrum disorders.
|
30824481 |
2019 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Longitudinally extensive transverse myelitis (LETM) accompanying systemic lupus erythematosus (SLE) is often due to coexisting aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder but has not been associated with myelin oligodendrocyte glycoprotein-IgG (MOG-IgG).
|
31621483 |
2019 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conducted a retrospective study of hospital case records of 294 individuals diagnosed with neuromyelitis optica (NMO) (G36.0 ICD-10, 341.0 ICD-9) in the Swedish National Patient Register from 1987 to end of 2013 or detected by the presence of aquaporin-4 (AQP4) immunoglobulin G (IgG) in serum during the study period.
|
31171648 |
2019 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
There is a consensus that the anti-aquaporin-4 antibody (AQP4-IgG) is the main pathogen detectable in majority of NMOSD patients, including traditional NMO and AQP4-IgG-positive optic neuritis.
|
30716473 |
2019 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.
|
30938427 |
2019 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
There were eleven AQP4-positive NMOSD patients in the study.
|
31731214 |
2019 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical trials for neuromyelitis optica treatments using anti-AQP4 IgG are in progress.
|
30934923 |
2019 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
All the patients showed disseminated lesions in the subcortical region to deep white matter, which were different from those found in MS and AQP4-Ab-positive NMOSD and were consistent with the characteristics of brain lesions in MOG-Ab-positive ADS, including other disease types.
|
30447856 |
2019 |
|
Neuromyelitis Optica
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conducted an open-label phase 1b safety and proof-of-concept trial in 5 subjects with aquaporin-4 (AQP4)-immunoglobulin G (IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD) who presented with acute transverse myelitis and/or optic neuritis.
|
31232925 |
2019 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum FAM19A5 was higher in patients with NMOSD-AQP4 and correlated with clinical characteristics.
|
31680620 |
2019 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although negative for aquaporin-4-IgG antibodies, the patient fulfilled criteria for seronegative neuromyelitis optica spectrum disorder with the presence of multiple core clinical characteristics.
|
30878968 |
2019 |
|
Neuromyelitis Optica
|
0.400 |
Biomarker
|
disease |
BEFREE |
Six children (10.3%) were diagnosed with acute disseminated encephalomyelitis, while seven young patients (20.6%) were diagnosed with aquaporin-4 antibody seronegative neuromyelitis optica spectrum disorder upon follow-up.
|
30904690 |
2019 |
|
Neuromyelitis Optica
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively collected data from 141 patients with NMOSD (104 with AQP4-IgG and 37 with MOG-IgG) and reviewed their clinical features and albumin quotient levels.
|
31812873 |
2019 |